

# Guido Rasi

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3444550/publications.pdf>

Version: 2024-02-01

93  
papers

3,836  
citations

81743

39  
h-index

128067

60  
g-index

96  
all docs

96  
docs citations

96  
times ranked

4536  
citing authors

#	ARTICLE	IF	CITATIONS
1	Randomized Controlled Trials Versus Real World Evidence: Neither Magic Nor Myth. <i>Clinical Pharmacology and Therapeutics</i> , 2021, 109, 1212-1218.	2.3	97
2	Increasing the impact of Post Authorisation Safety Studies: transparency is key. <i>European Journal of Internal Medicine</i> , 2021, 83, 6-7.	1.0	1
3	The COVID-19 crisis as an opportunity to strengthen global regulatory coordination for sustained enhanced access to diagnostics and therapeutics. <i>Clinical and Translational Science</i> , 2021, 14, 777-780.	1.5	2
4	Exploring the opportunities for alignment of regulatory postauthorization requirements and data required for performance-based managed entry agreements. <i>International Journal of Technology Assessment in Health Care</i> , 2021, 37, e83.	0.2	10
5	Legends of allergy and immunology: Sergio Bonini. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2021, 76, 3227-3229.	2.7	0
6	High CD169 Monocyte/Lymphocyte Ratio Reflects Immunophenotype Disruption and Oxygen Need in COVID-19 Patients. <i>Pathogens</i> , 2021, 10, 1639.	1.2	7
7	Are Novel, Nonrandomized Analytic Methods Fit for Decision Making? The Need for Prospective, Controlled, and Transparent Validation. <i>Clinical Pharmacology and Therapeutics</i> , 2020, 107, 773-779.	2.3	48
8	Big Data – How to Realize the Promise. <i>Clinical Pharmacology and Therapeutics</i> , 2020, 107, 753-761.	2.3	15
9	Pharmacovigilance 2030. <i>Clinical Pharmacology and Therapeutics</i> , 2020, 107, 89-91.	2.3	20
10	Clinical Trials for COVID-19: Can we Better Use the Short Window of Opportunity?. <i>Clinical Pharmacology and Therapeutics</i> , 2020, 108, 730-733.	2.3	22
11	Clinical trial publications: A sufficient basis for healthcare decisions?. <i>European Journal of Internal Medicine</i> , 2020, 71, 13-14.	1.0	4
12	Added therapeutic benefit and drug licensing. <i>Nature Reviews Drug Discovery</i> , 2019, 18, 651-652.	21.5	12
13	Data Rich, Information Poor: Can We Use Electronic Health Records to Create a Learning Healthcare System for Pharmaceuticals?. <i>Clinical Pharmacology and Therapeutics</i> , 2019, 105, 912-922.	2.3	76
14	The impact of parallel regulatory health technology assessment scientific advice on clinical development. Assessing the uptake of regulatory and health technology assessment recommendations. <i>British Journal of Clinical Pharmacology</i> , 2018, 84, 1013-1019.	1.1	34
15	Time to Review the Role of Surrogate End Points in Health Policy: State of the Art and the Way Forward. <i>Value in Health</i> , 2017, 20, 487-495.	0.1	101
16	How aligned are the perspectives of EU regulators and HTA bodies? A comparative analysis of regulatory HTA parallel scientific advice. <i>British Journal of Clinical Pharmacology</i> , 2016, 82, 965-973.	1.1	57
17	Drug Regulation and Pricing – Can Regulators Influence Affordability?. <i>New England Journal of Medicine</i> , 2016, 374, 1807-1809.	13.9	39
18	First-in-Human Clinical Trials – What We Can Learn from Tragic Failures. <i>New England Journal of Medicine</i> , 2016, 375, 1788-1789.	13.9	14

#	ARTICLE	IF	CITATIONS
19	Use of surrogate end points in healthcare policy: a proposal for adoption of a validation framework. <i>Nature Reviews Drug Discovery</i> , 2016, 15, 516-516.	21.5	32
20	From adaptive licensing to adaptive pathways: Delivering a flexible life <span>€</span> span approach to bring new drugs to patients. <i>Clinical Pharmacology and Therapeutics</i> , 2015, 97, 234-246.	2.3	160
21	Asthma, allergy and the Olympics. <i>Current Opinion in Allergy and Clinical Immunology</i> , 2015, 15, 184-192.	1.1	66
22	Steps forward in regulatory pathways for acute and chronic heart failure. <i>European Journal of Heart Failure</i> , 2015, 17, 3-8.	2.9	11
23	Innovative medicines: new regulatory procedures for the third millennium. <i>Expert Opinion on Biological Therapy</i> , 2015, 15, 5-8.	1.4	6
24	European regulatory experience with drugs for central nervous system disorders. <i>Nature Reviews Drug Discovery</i> , 2015, 14, 89-90.	21.5	1
25	Detection of high levels of <sc>S</sc>urvivin <span>€</span> immunoglobulin <sc>M</sc> immune complex in sera from hepatitis <sc>C</sc> virus infected patients with cirrhosis. <i>Hepatology Research</i> , 2014, 44, 1008-1018.	1.8	4
26	Transparency and the European Medicines Agency <span>€</span> Sharing of Clinical Trial Data. <i>New England Journal of Medicine</i> , 2014, 371, 2452-2455.	13.9	69
27	Proactively managing the risk of marketed drugs: experience with the EMA Pharmacovigilance Risk Assessment Committee. <i>Nature Reviews Drug Discovery</i> , 2014, 13, 395-397.	21.5	42
28	Cancer Drug Development and the Evolving Regulatory Framework for Companion Diagnostics in the European Union. <i>Clinical Cancer Research</i> , 2014, 20, 1458-1468.	3.2	40
29	Steps forward in regulatory pathways for acute and chronic heart failure. <i>ESC Heart Failure</i> , 2014, 1, 87-93.	1.4	4
30	WNT-pathway components as predictive markers useful for diagnosis, prevention and therapy in inflammatory bowel disease and sporadic colorectal cancer. <i>Oncotarget</i> , 2014, 5, 978-992.	0.8	54
31	The risks of risk aversion in drug regulation. <i>Nature Reviews Drug Discovery</i> , 2013, 12, 907-916.	21.5	87
32	Access to Patient-Level Trial Data <span>€</span> A Boon to Drug Developers. <i>New England Journal of Medicine</i> , 2013, 369, 1577-1579.	13.9	62
33	What we should learn from the London Olympics. <i>Current Opinion in Allergy and Clinical Immunology</i> , 2013, 13, 1-3.	1.1	9
34	Open Clinical Trial Data for All? A View from Regulators. <i>PLoS Medicine</i> , 2012, 9, e1001202.	3.9	92
35	Drug Policy for an Aging Population <span>€</span> The European Medicines Agency's Geriatric Medicines Strategy. <i>New England Journal of Medicine</i> , 2012, 367, 1972-1974.	13.9	111
36	Anti-proliferative effect of atrial natriuretic peptide on colorectal cancer cells: Evidence for an Akt-mediated cross-talk between NHE-1 activity and Wnt/ $\beta$ -catenin signaling. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2012, 1822, 1004-1018.	1.8	61

#	ARTICLE	IF	CITATIONS
37	Fifty years after thalidomide; what role for drug regulators?. British Journal of Clinical Pharmacology, 2012, 74, 731-733.	1.1	17
38	Evaluation of antigen specific recognition and cell mediated cytotoxicity by a modified lysis spot assay in a rat colon carcinoma model. Journal of Experimental and Clinical Cancer Research, 2012, 31, 9.	3.5	9
39	PCN99 ITALIAN MONITORING REGISTRY OF BEVACIZUMAB IN THE TREATMENT OF METASTATIC COLON RECTAL CARCINOMA. Value in Health, 2011, 14, A172.	0.1	0
40	TCTP is a critical survival factor that protects cancer cells from oxidative stress-induced cell-death. Experimental Cell Research, 2011, 317, 2479-2489.	1.2	45
41	Need for Redesigning Pharmacologic Research in Older Individuals. A Position Statement of the Geriatric Working Group of the Agenzia Italiana del Farmaco (AIFA). Journals of Gerontology - Series A Biological Sciences and Medical Sciences, 2011, 66A, 66-67.	1.7	12
42	A critical evaluation of the process of drug discovery and evaluation: is the current approach the best possible one?. Annali Dell'Istituto Superiore Di Sanita, 2011, 47, 1.	0.2	2
43	Transcription profile of human lymphocytes following <i>in vitro</i> treatment with thymosin alpha-1. Annals of the New York Academy of Sciences, 2010, 1194, 6-19.	1.8	17
44	Time to market and patient access to new oncology products in Italy: a multistep pathway from European context to regional health care providers. Annals of Oncology, 2010, 21, 2081-2087.	0.6	57
45	A cinque anni dal Decreto sugli studi "non profit", come eravamo e dove siamo. Italian Journal of Medicine, 2010, 4, 5-7.	0.2	0
46	The activation of human endogenous retrovirus K (HERV-K) is implicated in melanoma cell malignant transformation. Experimental Cell Research, 2009, 315, 849-862.	1.2	125
47	survivin-IgM immuno complex: A novel candidate biomarker of cirrhosis to monitor patients progression towards hepatocellular carcinoma. Digestive and Liver Disease, 2009, 41, A13.	0.4	1
48	AQUA: Allergy Questionnaire for Athletes. Development and Validation. Medicine and Science in Sports and Exercise, 2009, 41, 1034-1041.	0.2	88
49	Methodology for development of the Allergic Rhinitis and its Impact on Asthma Guideline 2008 update. Allergy: European Journal of Allergy and Clinical Immunology, 2008, 63, 38-46.	2.7	97
50	Stimulatory effect of Eucalyptus essential oil on innate cell-mediated immune response. BMC Immunology, 2008, 9, 17.	0.9	87
51	PACAP and VIP prevent apoptosis in schwannoma cells. Brain Research, 2008, 1241, 29-35.	1.1	64
52	Thymosin $\alpha$ 1 activates the TLR9/MyD88/IRF7-dependent murine cytomegalovirus sensing for induction of anti-viral responses in vivo. International Immunology, 2007, 19, 1261-1270.	1.8	49
53	Nerve growth factor involvement in liver cirrhosis and hepatocellular carcinoma. World Journal of Gastroenterology, 2007, 13, 4986.	1.4	38
54	Predictive value of allergy and pulmonary function tests for the diagnosis of asthma in elite athletes. Allergy: European Journal of Allergy and Clinical Immunology, 2007, 62, 1166-1170.	2.7	44

#	ARTICLE	IF	CITATIONS
55	Thymosin $\hat{A}1$ : An Endogenous Regulator of Inflammation, Immunity, and Tolerance. Annals of the New York Academy of Sciences, 2007, 1112, 326-338.	1.8	87
56	Immunopharmacology of Thymosin $\hat{A}1$ and Cytokine Synergy. Annals of the New York Academy of Sciences, 2007, 1112, 235-244.	1.8	16
57	Thymosin Alpha 1. Annals of the New York Academy of Sciences, 2007, 1112, 225-234.	1.8	41
58	524 POSTER Stimulatory effect of eucalyptus essential oil on macrophage/graulocyte phagocytic activity: in vitro and in vivo evidences. European Journal of Cancer, Supplement, 2006, 4, 159.	2.2	0
59	Lifestyle, Sports Activities and Allergic Diseases. Journal of Allergy and Clinical Immunology, 2006, 117, S294.	1.5	0
60	Epidemiological Study on Allergy and Asthma Phenotypes: Sub-clinical and Severe Asthma. Journal of Allergy and Clinical Immunology, 2006, 117, S1.	1.5	0
61	Nerve Growth Factor Regulates the Production of Lung Mucins in a Transgenic Mice Model of Asthma. Journal of Allergy and Clinical Immunology, 2006, 117, S250.	1.5	1
62	Feasibility of in utero DNA vaccination following naked gene transfer into pig fetal muscle: Transgene expression, immunity and safety. Vaccine, 2006, 24, 4586-4591.	1.7	21
63	Thymosin $\hat{A}1$ activates dendritic cell tryptophan catabolism and establishes a regulatory environment for balance of inflammation and tolerance. Blood, 2006, 108, 2265-2274.	0.6	172
64	Rhinitis and asthma in athletes: an ARIA document in collaboration with GA2LEN. Allergy: European Journal of Allergy and Clinical Immunology, 2006, 61, 681-692.	2.7	96
65	Differentiation of human melanoma cells induced by cyanidin-3-O- $\hat{A}$ glucopyranoside. FASEB Journal, 2004, 18, 1940-1942.	0.2	48
66	Thymosin $\hat{A}1$ activates dendritic cells for antifungal Th1 resistance through Toll-like receptor signaling. Blood, 2004, 103, 4232-4239.	0.6	189
67	Diagnosis of asthma and permitted use of inhaled beta2-agonists in athletes. Allergy: European Journal of Allergy and Clinical Immunology, 2004, 59, 33-36.	2.7	24
68	Vaccination with a synthetic nonapeptide expressed in human tumors prevents colorectal cancer liver metastases in syngeneic rats. International Journal of Cancer, 2004, 110, 70-75.	2.3	6
69	Combination therapy in the treatment of chronic viral hepatitis and prevention of hepatocellular carcinoma. International Immunopharmacology, 2003, 3, 1169-1176.	1.7	28
70	Thymosin $\hat{A}1$ in combination with cytokines and chemotherapy for the treatment of cancer. International Immunopharmacology, 2003, 3, 1145-1150.	1.7	37
71	Nerve Growth Factor: Neurotrophin or Cytokine?. International Archives of Allergy and Immunology, 2003, 131, 80-84.	0.9	104
72	Montelukast, a Leukotriene Receptor Antagonist, in Vernal Keratoconjunctivitis Associated With Asthma. JAMA Ophthalmology, 2003, 121, 615.	2.6	37

#	ARTICLE	IF	CITATIONS
73	Nerve growth factor and asthma. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2002, 57, 13-15.	2.7	41
74	Combined treatment with thymosin- $\hat{1}$ and low dose interferon- $\hat{1}$ after dacarbazine in advanced melanoma. <i>Melanoma Research</i> , 2000, 10, 189-192.	0.6	25
75	A new human tumor-associated antigen (TLP) is naturally expressed in rat DHD-K12 colorectal tumor cells. , 2000, 85, 540-544.		8
76	Thymosin alpha 1 in the treatment of cancer: from basic research to clinical application. <i>International Journal of Immunopharmacology</i> , 2000, 22, 1067-1076.	1.1	44
77	Expression profile of saccharide epitope CaMBr1 in normal and neoplastic tissue from dogs, cats, and rats: implication for the development of human-derived cancer vaccines. <i>The Histochemical Journal</i> , 1999, 31, 729-737.	0.6	4
78	Nanopore Technology for Biomedical Applications. <i>Biomedical Microdevices</i> , 1999, 2, 11-40.	1.4	172
79	Microfabricated biocapsules provide short-term immunoisolation of insulinoma xenografts. <i>Biomedical Microdevices</i> , 1999, 1, 131-138.	1.4	85
80	Efficacy of repeated cycles of chemo-immunotherapy with Thymosin $\hat{1}$ and interleukin-2 after intraperitoneal 5-fluorouracil delivery. <i>Cancer Immunology, Immunotherapy</i> , 1999, 48, 172-178.	2.0	19
81	Differential Expression of a New Tumor-Associated Antigen, TLP, During Human Colorectal Cancer Tumorigenesis. <i>American Journal of Pathology</i> , 1999, 154, 993-999.	1.9	11
82	Atopic and Vernal Keratoconjunctivitis: A Model for Studying Atopic Disease. , 1999, 28, 88-94.		8
83	<title>Implantation of microfabricated immunoisolating biocapsules</title>. , 1998, 3258, 40.		10
84	Combination therapy with BRMs in cancer and infectious diseases. <i>Mechanisms of Ageing and Development</i> , 1997, 96, 103-116.	2.2	6
85	Combination low-dose lymphoblastoid interferon and thymosin $\hat{1}$ therapy in the treatment of chronic hepatitis B. <i>Journal of Viral Hepatitis</i> , 1996, 3, 191-196.	1.0	48
86	Combination thymosin alpha 1 and lymphoblastoid interferon treatment in chronic hepatitis C.. <i>Gut</i> , 1996, 39, 679-683.	6.1	44
87	Sequential biochemotherapy for metastatic colorectal cancer using fluorouracil, folinic acid, thymopentin and interleukin-2: Clinical and immunological effects. <i>Annals of Oncology</i> , 1995, 6, 1011-1017.	0.6	14
88	Sequential chemoimmunotherapy for advanced non-small cell lung cancer using cisplatin, etoposide, thymosin- $\hat{1}$ and interferon- $\hat{1}$ 2a. <i>European Journal of Cancer</i> , 1995, 31, 2403-2405.	1.3	40
89	Anti-tumor effect of combined treatment with thymosin alpha 1 and interleukin-2 after 5-fluorouracil in liver metastases from colorectal cancer in rats. <i>International Journal of Cancer</i> , 1994, 57, 701-705.	2.3	41
90	Biochemotherapy with thymosin $\hat{1}$ , interleukin-2 and dacarbazine in patients with metastatic melanoma: Clinical and immunological effects. <i>Annals of Oncology</i> , 1994, 5, 741-746.	0.6	31

#	ARTICLE	IF	CITATIONS
91	Combination therapy with thymosin $\hat{\pm}$ 1 potentiates the anti-tumor activity of interleukin-2 with cyclophosphamide in the treatment of the lewis lung carcinoma in mice. International Journal of Cancer, 1992, 50, 493-499.	2.3	48
92	Rationale for Therapeutic Approaches with Thymosin $\hat{\pm}$ 1, Interleukin 2 and Interferon in Combination with Chemotherapy. , 1992, , 275-281.		4
93	45 Atopy in twins. Journal of Allergy and Clinical Immunology, 1983, 71, 100.	1.5	3